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Abstract
Introduction: Exercise may improve cancer outcomes. Neoadjuvant chemotherapy (NC) for breast cancer provides a unique setting to 
evaluate intervention effects. Treatments leading to decreased post-neoadjuvant Ki-67 levels, smaller tumor size, and higher pathologic 
response are associated with improved survival and lower recurrence. This randomized, prospective pilot trial evaluates the feasibility 
of supervised exercise during NC for breast cancer.
Methods: Stage II-III, ER positive, cancer patients with BMI . 25 receiving NC were randomized to standard NC with   supervised 
  bootcamp (NC + BC) or NC alone. Ki-67, C-peptide, BMI, and tumor size were measured before chemotherapy and at time of surgery. 
Results: There were no initial differences between groups in regards to tumor size, C-peptide, BMI, and Ki−67. The NC + BC (n = 5) 
group had a lower mean BMI at the conclusion of NC compared with those (n = 5) in the NC group (28.0 versus 35.8, P = 0.03). Final 
tumor size was 2.59 cm in the NC + BC group versus 3.16 cm for NC (P = 0.76) Mean Ki-67 for NC + BC was 7% versus 29% with NC 
(P = 0.14). C-peptide (ng/mL) was equivalent between the two groups (4.55 NC + BC versus 4.74 NC, P = 0.85).
Conclusions: Adding a supervised exercise program to NC is feasible, decreases BMI, and may lead to lower Ki-67 levels and improved 
survival.
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Introduction
A  growing  body  of  evidence  suggests  that  cancer  patients 
may benefit from physical activity.1–7 The majority of 
previous studies have focused on impact upon qual-
ity  of  life6–8  amongst  survivors.  Research  reveals 
improvements in cardio-respiratory fitness, physical 
functioning, and decreased fatigue in   cancer patients 
who receive exercise interventions.8 There is some 
evidence, however, that there may also be decreased 
rates of breast cancer specific   mortality in survivors 
who engage in increased physical activity.1,3
Although most studies evaluating physical   activity 
and breast cancer indicate a favorable impact,3–5 the 
generally  excellent  prognosis  from  multi-  modality 
treatment  of  breast  cancer  in  the  United  States9 
makes it difficult to isolate the effect of the   exercise 
itself.  The  majority  of  research  on  breast  cancer 
and   physical activity evaluates exercise in the post-
treatment  setting,3,5,10–14  even  though  the  ability  to 
impact lifestyle changes may be at the time of initial 
diagnosis.15
This study was therefore designed to evaluate the 
feasibility and impact of a supervised exercise regimen 
given  during  neoadjuvant  chemotherapy  for  breast 
cancer, a time when patients may be more receptive to 
lifestyle changes. For patients with locally advanced 
breast cancer, neoadjuvant chemotherapy is the ini-
tial treatment of choice.16 Neoadjuvant chemotherapy 
allows for an immediate assessment of response and 
can provide valuable information regarding progno-
sis and therapeutic efficacy.17,18
To the best of our knowledge, this study is the first 
randomized pilot trial to take advantage of the well-
known prognostic value of response to neoadjuvant 
chemotherapy  in  order  to  evaluate  the  efficacy,  as 
defined by known prognostic biomarker changes, of a 
supervised bootcamp exercise intervention in patients 
with locally advanced breast cancer.
Methods
This study was approved by the Institutional Review 
Board  of  the  University  of  Texas    Southwestern 
M  edical  Center,  all  patients  were  diagnosed  and 
treated  between  March,  2009  and  April,  2011. 
Women  undergoing  neoadjuvant  chemotherapy 
for locally advanced, non-metastatic breast cancer 
were randomized to the bootcamp arm (an exercise 
  protocol  supervised  by  an  experienced  personal 
trainer) or chemotherapy alone. Randomization was 
performed  by  reviewing  the  study  protocol  with 
  eligible  patients.  Once  they  had  been  consented 
for the study, an unlabeled envelope was opened 
by the research coordinator to place the patient in 
either the control or bootcamp arm of the study. To 
be    eligible  for  the  protocol,  patients  had  to  have 
  estrogen receptor positive breast cancer and have 
a body mass index (BMI) greater than 25. Insulin 
dependent  diabetic  patients  were  excluded.  This 
design allowed for a uniform group of patients who 
were unlikely to have previously exercised, and who 
had similar tumor features and consequently would 
have been expected to have equivalent responses to 
standard neoadjuvant chemotherapy. Approximately 
500 breast cancer patients are treated annually at the 
cancer center, review of tumor registry data estimated 
80 patients would meet all inclusion/exclusion cri-
teria for this study every year. 10 patients ultimately 
met all criteria and agreed to participate. All eligible 
patients were approached by study coordinators to 
discuss study participation. Patients received stan-
dard  neoadjuvant  chemotherapy  at  the  discretion 
of the medical oncologist, per institutional proto-
cols, with the standard institutional regimen being 
dose  dense  adriamycin,  cyclophosphamide  and 
taxol (AC + T). Exercise for the bootcamp arm was 
started within one week of the first chemotherapy 
cycle. Specific endpoints evaluated both before and 
after chemotherapy were Ki-67 in the tumor, tumor 
size,  axillary  lymph  node  status,  insulin  growth 
factor 1(IGF-1) levels, C-peptide levels, and BMI. 
Clinical  and  pathologic  response  to  neoadjuvant 
chemotherapy at the breast and axillary site were 
also recorded (Fig. 1).
exercise intervention
The  exercise  regimen  chosen  involved  a  boot-
camp program which included both aerobic train-
ing  and  resistance  activities.  Resistance  activity 
is  associated  with  improvements  in  lean  body 
mass,19 which may impact insulin resistance, and 
this was therefore incorporated into the exercise 
program. Aerobic training is important for overall 
cardio-respiratory health, and was therefore also 
included in the bootcamp program. During the ses-
sions,  patients  engaged  in  intervals  of  activities 
such as jumping jacks, running in place, arm and Bootcamp during neoadjuvant chemotherapy
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leg work with exercise balls, bands, and weights 
up  to  5  pounds.  Patients  were  pushed  to  their 
individual tolerance levels, a total of 48 sessions 
were prescribed. To optimize   compliance, patients 
were allowed to choose whether they preferred a 
home based regimen where a personal trainer came 
to the patients house for 1 hour three times a week, 
or if they wished to participate in a group session, 
open to the public, that occurred 5 days a week, 
with the patients on trial only required to attend 
three times per week.
Biomarker rationale
Ki-67
Human Ki-67 is a protein associated with cell pro-
liferation. It has significant value for predicting sur-
vival and recurrence risk in cancer patients.18,20,21 Post 
neoadjvuant  chemotherapy  Ki-67  of  ,12%  corre-
lates with reduced rates of recurrence.22 In addition, 
greater decreases in Ki-67 in breast cancer patients 
correlate with improved disease-free survival, over-
all survival, and lower rates of recurrence.21–23 Ki-67 
was measured in the initial core biopsy specimen and 
then again in the final resection specimen removed 
for definitive surgical intervention after neoadjuvant 
chemotherapy.  Ki-67  was  reported  outside  of  the 
standard pathology report and interpreted by a single 
breast pathology fellowship trained pathologist who 
was not aware of which study arm the patient was in.
immunohistochemistry (ihC) assay and image 
quantitation methods for Ki-67
Quantitative IHC was used to determine Ki-67 expres-
sion in the breast tumors. IHC staining was performed 
using  a  TechMate  1000  automated  immunostainer 
(Ventana Medical Systems, Tucson, Arizona). A known 
positive control section was included in each run to 
assure proper staining. Rabbit immunoglobulin frac-
tion (Normal) or non-specific IgG1 monoclonal diluted 
with PBS was used as a negative control. A monoclo-
nal antibody was used for Ki-67 (MIB-1, predilute, 
Ventana Medical Systems, Tucson, Arizona).
Quantitative information for staining was obtained 
using  the  automated  microscopy  method,  Ventana 
Imaging Analysis System (VIAS, Ventana Medical 
Systems, Tucson, Arizona). The microscope module 
scanned the immunohistochemically stained slides, 
and the computer monitor displayed the digitalized 
tissue images. After viewing the high-magnification 
images on the VIAS computer, several subregions of 
the digitalized tissue images were selected for analy-
sis by the VIAS. Positivity of Ki-67 was determined 
by  the  presence  of  nuclear  staining.  Grading  was 
based on the percentage of stained tumor cells.
ER+, Tumor size > 3.0 cm,
BMI > 25
Consented,
randomized, Ki-67,
IGF-1, C-peptide, BMI
Neoadjuvant
chemotherapy alone
Neoadjuvant
chemotherapy +
bootcamp
Surgery
Ki-67, IGF-1,
C-peptide, BMI
Surgery
Ki-67, IGF-1,
C-peptide, BMI
Figure 1. Study design. 
note: Schema of randomized pilot trial.
Abbreviations: eR, estrogen receptor; BMi, body mass index; igF-1, igF-insulin like growth factor 1.Rao et al
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igF-1and C-petide
There appears to be a link between insulin resistance 
(IR) and breast cancer.24–28 Additionally, patients in 
exercise  programs  demonstrate  decreased  IR.26,29 
Decreased resistance to insulin may, in part, account 
for improved outcomes in breast cancer survivors who 
engage in physical activity.1 Fasting serum C-peptide 
levels were monitored as an indicator of insulin resis-
tance as was IGF-1, which have been shown to be 
influenced  by  exercise.30  Decreasing  insulin  resis-
tance may provide this survival benefit by decreasing 
cancer cell proliferation.
Student’s t-test was performed to examine the dif-
ference of each outcome measure between the control 
group and the bootcamp group. The comparison was 
performed before and after neoadjuvant chemother-
apy, respectively. The changes of the outcome before 
and  after  treatment  were  also  compared  between 
these two groups by t test. All reported P-values are 
two-sided and the statistical analyses were conducted 
using  SAS  9.2  for  Windows  (SAS  Institute  Inc., 
Cary, NC).
Results
Ten patients were randomized and completed all study 
parameters and were included in this analysis. All 
five patients in the bootcamp group completed .80% 
of the advised exercise sessions, all patients in the 
  control arm received chemotherapy and underwent 
the required blood draws. Mean age for all patients at 
the time of diagnosis was 55 years, and mean tumor 
size was 4.97 cm (Table 1). The majority of patients 
found  their  tumors  on  breast  self  exam,  and  most 
patients had an invasive ductal carcinoma on pathol-
ogy (Table 1). Five patients (3 controls and 2 study) did 
not meet standard indications for genetic testing, and 
it was therefore not offered. Four patients (1 control, 
3 study) were tested and found to be negative for 
BRCA1/2 mutations, 1 patient in the control group 
was diagnosed as a BRCA2 mutation carrier. Nine 
patients received AC + T, one patient in the control 
arm received taxotere, carboplatin and   trastuzumab. 
All  neoadjuvant  chemotherapy  was  completed  in 
4–6 months after diagnosis, bootcamp was given dur-
ing this entire time. There were no statistically signif-
icant differences between groups in regards to tumor 
size, age, BMI, tumor grade, C-  peptide levels, or ini-
tial Ki-67 (Table 1). All patients had axillary nodal 
metastases  and  subsequently  underwent  comple-
tion axillary lymph node dissection (ALND). Seven 
patients were diagnosed with the axillary metastases 
via  ultrasound  guided  percutaneous  needle  biopsy 
prior to starting neoadjuvant chemotherapy, 6 patients 
underwent core needle biopsy, and 1 underwent fine 
needle aspiration. The additional 3 patients had ini-
tial clinically and sonographically negative axillas, 
Table 1. initial characteristics.
control Bootcamp All P-value
Age (mean) 51.4 59.8 55.6 0.21
Tumor type 
  invasive ductal carcinoma 
  invasive lobular carcinoma
 
4 
1
 
4 
1
 
8 
2
 
1.00
initial tumor size (mean) cm 4.88 5.06 4.97 0.91
Method of tumor detection 
  Breast self exam 
  Mammogram
 
4 
1
5 
0
 
9 
1
 
1.00
Pre-op BMi (mean) 36.59 30.57 33.58 0.13
initial Ki-67% (mean) 42 34 38 0.56
grade 
  ii 
  iii
 
1 
4
 
3 
2
 
4 
6
 
0.52
Axillary metastases diagnosis 
  Percutaneous biopsy 
  Sentinel node
 
3 
2
 
4 
1
 
7 
3
1.00
initial C-peptide (mean) ng/mL 6.57 5.80 6.18 0.81
initial igF-1 (mean) ng/mL 187.7 (n = 3) 130.7 (n = 3) 159.2 0.052
Abbreviations: BMi, body mass index; igF, insulin like growth factor 1.Bootcamp during neoadjuvant chemotherapy
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and therefore underwent sentinel node biopsy at the 
completion of neoadjvuant chemotherapy. All 3 were 
found to have axillary nodal metastases and under-
went ALND (Table 1).
At the time of surgical intervention, along with 
their ALND, 6 patients underwent total mastectomy, 
and 4 underwent partial mastectomy. There were a 
median of 8.6 positive nodes at ALND (range = 1–16) 
in  the  bootcamp  group  versus  2.4  positive  nodes 
(range = 0–8) in the control group. Final pathologic 
tumor size was equivalent between the two groups 
(Table 2). Residual cancer burden (RCB)31 was Class 
III in three patients (2 in the bootcamp group and 
1 in the control), Class II in six patients (3 bootcamp, 
3 control) and Class I in one control patient.
For  bootcamp  patients,  mean  Ki-67  level  after 
  neoadjuvant chemotherapy was 7.2% (7.2% ± 2.8%) 
versus 29.2% (29.2% ± 12.0%) in the control group 
(Table 2 and Fig. 2A and B). Fasting C-peptide levels 
decreased in both groups, and there was no statisti-
cally significant difference between the two groups 
after neoadjuvant chemotherapy (Table 2). BMI in 
the control group was 35.8 (35.8 ± 2.7), versus 28.0 
(28.0 ± 1.0) in the bootcamp group after neoadju-
vant chemotherapy, which was a statistically signifi-
cant difference (P = 0.03, Table 2). BMI change and 
C-peptide change, when evaluated for each individ-
ual patient, was also greater in the bootcamp group 
(Figs. 2A and B and 3A and B), although this was 
not  statistically  significant  (Table  2).  Mean  BMI 
change in the control group was 0.79 ± 0.69 versus 
2.54 ± 1.47 in the bootcamp group (P = 0.32) Initial 
IGF-1 was collected for 3 patients in the bootcamp 
group, mean initial IGF-1 was 130.7 and increased to 
160 at the conclusion of neoadjuvant chemotherapy. 
The   control group had 3 patients with a mean initial 
IGF-1 of 187.7 and the follow-up IGF-1 was 171.0. 
The change in IGF-1 between the two groups was 
not statistically significant (P = 0.31). At a median 
follow-up of 21.6 months, there has been no local or 
systemic recurrence in either group. All patients con-
tinue to take adjuvant hormonal therapy. Multivariate 
analysis was attempted to ascertain factors predicting 
a Ki-67 of ,12% after chemotherapy, no significant 
factors were identified, likely due to the small sample 
size in this pilot study.
Discussion
This pilot study reveals the feasibility of an exercise 
intervention  for  patients  undergoing  neoadjvuant 
chemotherapy for breast cancer. The study is clearly 
limited by its small sample size, but does provide an 
innovative framework for incorporation of physical 
activity into a patient’s lifestyle.
C-peptide and BMi
The  reductions  in  C-peptide  levels  in  the  exercise 
group  were  not  as  significant  as  expected.  Irwin32 
et  al  examined  the  association  between  C-peptide 
levels  and  breast  cancer  death  amongst  survivors. 
A C-peptide level greater than 2.5 ng/mL correlated 
with a two-fold increased risk of breast cancer death 
when compared to those women who’s C-peptides 
were ,1.7 ng/mL (HR 2.39, 95% CI 1.00–7/50). One 
explanation for the lack of C-peptide reductions may 
be the patients’ BMI. There appears to be an asso-
ciation  between  BMI  and  C-peptide  levels,33  and 
although BMI reductions were noted in the bootcamp 
group, these may not have been drastic enough to 
influence C-peptide levels to ,1.7.
In the bootcamp arm, 4 of 5 patients continued to 
be overweight, as defined by a BMI of 25–30, at the 
  conclusion  of  the  study.  One  bootcamp  patient  was 
able to achieve a normal BMI of ,25. In contrast, for 
Table 2. Analysis after intervention.
control Bootcamp P-value
Post-chemotherapy pathologic tumor size (mean) cm 3.16 2.59 0.76
Post-chemotherapy Ki-67% (mean) 29 7 0.14
Change in Ki-67% (mean ± SeM) 27.2 ± 7.6 13.2 ± 11.7 0.35
Post-chemotherapy BMi (mean) 35.8 28.0 0.03
BMi change (mean ± SeM) 0.79 ± 0.69 2.54 ± 1.47 0.32
Post-chemotherapy C-peptide (mean) ng/mL 4.74 4.55 0.85
Abbreviations: BMi, body mass index; SeM, standard error of the mean.Rao et al
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patients receiving neoadjuvant chemotherapy alone, 4 of 
5 patients were morbidly obese, as defined by a BMI of 
.35, and 1 patient was overweight at study conclusion.
igF-1
Studies reveal an association between lower IGF-1 
levels  and  signs  or  symptoms  of  cardiovascular 
disease.34  Therefore,  the  increases  in  IGF-1  levels 
demonstrated  in  the  bootcamp  arm  are  potentially 
reflective of improved cardiovascular fitness due to 
exercise, and may decrease mortality in this patient 
population.
Compliance
Overall compliance with bootcamp in this   prospective 
pilot trial was excellent. Despite the well known ben-
efits of exercise, compliance with increased physi-
cal activity regimens is poor.35 Barriers to exercise 
for cancer patients in particular include distance to 
travel  for  exercise,  and  a  lack  of  recommendation 
by a physician.15 The home based exercise program 
utilized  in  this  protocol  overcomes  both  of  these 
issues,   subsequently compliance with this   protocol 
was  very  high  with  all  patients  in  the  bootcamp 
group   completing at least 80% of the advised exer-
cise   sessions. The   current bootcamp protocol requires 
intensive  one-  on-one  supervision,  and  while  the 
utilization of resources up front are significant, the 
decreased BMI in the exercise group and adherence 
to the protocol may predict higher long-term com-
mitment  to  increased  physical  activity  and  a  true 
behavioral change for these patients.36 In addition, 
the weight gain normally seen with chemotherapy37,38 
was not observed in the patients in the exercise arm,   
a factor which may also improve long term survival.
Future directions
The results from this pilot study are promising, and 
support the use of and feasibility of exercise regi-
mens in the neoadjuvant setting. Exercise may be a 
potentially useful tool for impacting tumor biology, 
in  addition  to  the  known  quality  of  life  improve-
ments. Future studies are planned to validate these 
results  in  a  multi-institutional,  prospective  trial  to 
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Figure 2. Ki-67 change.
notes: Ki-67 initial reflects Ki-67 in core biopsy sample, final reflects Ki-67 after neoadjuvant chemotherapy in final surgical specimen for each patient. 
Bootcamp arm had marked changes in Ki-67, a potential indicator of improved breast cancer prognosis.
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Figure 3. BMi change. 
notes: Patient BMI at the time of diagnosis and at the conclusion of neaodjuvant chemotherapy. Statistically significant changes (P = 0.03) in BMi were 
noted in the bootcamp arm.Bootcamp during neoadjuvant chemotherapy
Breast Cancer: Basic and Clinical Research 2012:6  45
provide    adequate  power  and  potentially  statistical 
significance. Additionally,  further  studies  to  deter-
mine  the  minimum  “dose”  of  exercise  required  to 
achieve lower Ki-67 levels are also needed.
conclusion
This pilot study supports the feasibility and potential 
benefits from a focused exercise intervention given 
during neoadjuvant chemotherapy for breast cancer.
Acknowledgment
The authors wish to thank the patients who partici-
pated in this trial, Dallas County Bootcamp, Com-
mercial Real Estate Women’s group of Dallas, Linda 
Flores, and Madhu Rao.
Financial  support  received  from  a  grant  given 
by the Commercial Real Estate Women of Dallas, 
  Clinicaltrials.gov: NCT0141178.
Disclosures
Author(s) have provided signed confirmations to the 
publisher of their compliance with all applicable legal 
and ethical obligations in respect to declaration of 
conflicts of interest, funding, authorship and contrib-
utorship, and compliance with ethical requirements 
in  respect  to  treatment  of  human  and  animal  test 
subjects. If this article contains identifiable human 
subject(s) author(s) were required to supply signed 
patient consent prior to publication. Author(s) have 
confirmed that the published article is unique and not 
under consideration nor published by any other pub-
lication and that they have consent to reproduce any 
copyrighted material. The peer reviewers declared no 
conflicts of interest.
References
1.  Ogunleye AA, Holmes MD. Physical activity and breast cancer survival. 
Breast Cancer Res. 2009;11:106.
2.  Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical activity and 
survival after colorectal cancer   diagnosis. J Clin Oncol. 2006;24:3527–34.
3.  Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical 
  activity and survival after breast cancer diagnosis. JAMA. 2005;293:2479–86.
4.  Jones LW, Douglas PS, Eves ND, et al. Rationale and design of the   Exercise 
Intensity  Trial  (EXCITE):  a  randomized  trial  comparing  the  effects  of 
  moderate versus moderate to high-intensity aerobic training in women with 
operable breast cancer. BMC Cancer. 2010;10:531.
5.  Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast   cancer 
in physically active women with high vegetable-fruit intake regardless of 
obesity. J Clin Oncol. 2007;25:2345–51.
6.  Abrahamson  PE,  Gammon  MD,  Lund  MJ,  et  al.  Recreational  physical 
activity  and  survival  among  young  women  with  breast  cancer.  Cancer. 
2006;107:1777–85.
  7.  Reigle BS, Wonders K. Breast cancer and the role of exercise in women.
Methods Mol Biol. 2009;472:169–89.
  8.  McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. 
Effects of exercise on breast cancer patients and survivors: a systematic review 
and meta-analysis. CMAJ. 2006;175:34–41.
  9.  Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 
2010;60:277–300.
  10.  Holick  CN,  Newcomb  PA,  Trentham-Dietz  A,  et  al.  Physical  activity 
and   survival after diagnosis of invasive breast cancer. Cancer Epidemiol 
  Biomarkers Prev. 2008;17:379–86.
  11.  Irwin ML, Smith AW, McTiernan A, et al. Influence of pre- and   postdiagnosis 
physical activity on mortality in breast cancer survivors: the health, eating, 
activity, and lifestyle study. J Clin Oncol. 2008;26:3958–64.
  12.  West-Wright CN, Henderson KD, Sullivan-Halley J, et al. Long-term and 
recent recreational physical activity and survival after breast   cancer: the 
California Teachers Study. Cancer Epidemiol Biomarkers Prev. 2009;18: 
2851–9.
  13.  Ligibel JA, Giobbie-Hurder A, Olenczuk D, et al. Impact of a mixed strength 
and endurance exercise intervention on levels of adiponectin, high molecu-
lar weight adiponectin and leptin in breast cancer survivors. Cancer Causes 
Control. 2009;20:1523–8.
  14.  Ligibel JA, Campbell N, Partridge A, et al. Impact of a mixed strength and 
endurance exercise intervention on insulin levels in breast cancer survivors. 
J Clin Oncol. 2008;26:907–12.
  15.  Stull VB, Snyder DC, Demark-Wahnefried W. Lifestyle interventions in 
cancer survivors: designing programs that meet the needs of this vulnerable 
and growing population. J Nutr. 2007;137:243S–8S.
  16.  Carlson RW, Allred DC, Anderson BO, et al. Breast cancer: Clinical prac-
tice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:122–92.
  17.  Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from 
an international expert panel on the use of neoadjuvant (primary) systemic 
treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 
2007;18:1927–34.
  18.  Lee J, Im YH, Lee SH, et al. Evaluation of ER and Ki-67 proliferation index 
as  prognostic  factors  for  survival  following  neoadjuvant  chemotherapy 
with  doxorubicin/docetaxel  for  locally  advanced  breast  cancer.  Cancer 
Chemother Pharmacol. 2008;61:569–77.
  19.  Courneya KS, Segal RJ, Mackey JR, et al. Effects of aerobic and resistance 
exercise in breast cancer patients receiving adjuvant chemotherapy: a mul-
ticenter randomized controlled trial. J Clin Oncol. 2007;25:4396–404.
  20.  Polcher M, Friedrichs N, Rudlowski C, et al. Changes in Ki-67 labeling 
indices during neoadjuvant chemotherapy for advanced ovarian cancer are 
associated with survival. Int J Gynecol Cancer. 2010;20:555–60.
  21.  Guarneri V, Piacentini F, Ficarra G, et al. A prognostic model based on nodal 
status and Ki-67 predicts the risk of recurrence and death in breast cancer 
patients with residual disease after preoperative chemotherapy. Ann Oncol. 
2009;20:1193–8.
  22.  Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical signifi-
cance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as 
a predictor for chemosensitivity and for prognosis. Breast Cancer. 2010;17: 
269–75.
 23.  Billgren  AM,  Rutqvist  LE,  Tani  E,  Wilking  N,  Fornander  T,  Skoog  L. 
  Proliferating fraction during neoadjuvant chemotherapy of primary breast can-
cer in relation to objective local response and relapse-free survival. Acta Oncol. 
1999;38:597–601.
  24.  Vatten  LJ,  Holly  JM,  Gunnell  D,  Tretli  S.  Nested  case-control  study 
of  the  association  of  circulating  levels  of  serum  insulin-like  growth 
factor I and i  nsulin-like growth factor binding protein 3 with breast cancer 
in young women in Norway. Cancer Epidemiol Biomarkers Prev. 2008;17: 
2097–100.
  25.  Espelund U, Cold S, Frystyk J, Orskov H, Flyvbjerg A. Elevated free IGF2 
levels in localized, early-stage breast cancer in women. Eur J Endocrinol. 
2008;159:595–601.
  26.  Goodwin PJ, Ennis M, Pritchard KI, et al. Insulin-like growth factor bind-
ing proteins 1 and 3 and breast cancer outcomes. Breast Cancer Res Treat. 
2002;74:65–76.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
Rao et al
46  Breast Cancer: Basic and Clinical Research 2012:6
  27.  Ibrahim YH, Yee D. Insulin-like growth factor-I and breast cancer therapy. 
Clin Cancer Res. 2005;11:944s–50s.
  28.  Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in 
early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 
2002;20:42–51.
  29.  Barnard RJ, Gonzalez JH, Liva ME, Ngo TH. Effects of a low-fat, high-fiber 
diet and exercise program on breast cancer risk factors in vivo and tumor 
cell growth and apoptosis in vitro. Nutr Cancer. 2006;55:28–34.
  30.  Irwin ML, Varma K, Alvarez-Reeves M, et al. Randomized controlled trial 
of aerobic exercise on insulin and insulin-like growth factors in breast   cancer 
survivors:  the Yale  Exercise  and  Survivorship  study.  Cancer    Epidemiol 
  Biomarkers Prev. 2009;18:306–13.
  31.  Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast 
cancer burden to predict survival after neoadjuvant chemotherapy. J Clin 
Oncol. 2007;25:4414–22.
  32.  Irwin ML, Duggan C, Wang CY, et al. Fasting C-peptide levels and death 
resulting from all causes and breast cancer: the health, eating, activity, and 
lifestyle study. J Clin Oncol. 2011;29:47–53.
  33.  Keinan-Boker  L,  Bueno  De  Mesquita  HB,  et  al.  Circulating  levels  of 
  insulin-like growth factor I, its binding proteins -1,-2,-3, C-peptide and risk of 
postmenopausal breast cancer. Int J Cancer. 2003;106:90–5.
  34.  Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total 
IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to 
cardiovascular  risk  factors  and  disease.  Arterioscler  Thromb  Vasc  Biol. 
1998;18:277–82.
  35.  Williams NH, Hendry M, France B, Lewis R, Wilkinson C. Effectiveness of 
exercise-referral schemes to promote physical activity in adults: systematic 
review. Br J Gen Pract. 2007;57:979–86.
  36.  Courneya KS, Friedenreich CM, Reid RD, et al. Predictors of follow-up 
  exercise behavior 6 months after a randomized trial of exercise training 
during breast cancer chemotherapy. Breast Cancer Res Treat. 2009;114: 
179–87.
  37.  Del  Rio  G,  Zironi  S,  Valeriani  L,  et  al.  Weight  gain  in  women  with 
breast cancer treated with adjuvant cyclophosphomide,   methotrexate and 
5-  fluorouracil. Analysis of resting energy expenditure and body   composition. 
Breast Cancer Res Treat. 2002;73:267–73.
  38.  Demark-Wahnefried  W,  Kenyon  AJ,  Eberle  P,  Skye  A,  Kraus  WE. 
  Preventing sarcopenic obesity among breast cancer patients who receive 
adjuvant   chemotherapy: results of a feasibility study. Clin Exerc Physiol. 
2002;4:44–9.